# Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

> **NCT00134953** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 24 (—)

## Conditions studied

- Cognitive Symptoms

## Interventions

- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT00134953
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 24 (—)
- **Why stopped:** The Principal Investigator left the clinic and there was no one who could take over this study.
- **Last updated:** 2007-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134953, "Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00134953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*